Spero Therapeutics (SPRO) Income from Continuing Operations (2016 - 2026)
Spero Therapeutics posted quarterly Income from Continuing Operations of 7202000.0 for Q1 2026, up 48.06% year-on-year from 4864121.08 in Q1 2025, and down 122.85% on a QoQ basis from 31520000.0 in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Income from Continuing Operations data on file, last reported at 7202000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 48.06% year-over-year to 7202000.0; the trailing twelve-month figure through Mar 2026 stood at 15230000.0 (up 120.72% YoY), and the FY2025 full-year result was 8565000.0, up 112.48% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 7202000.0, down from 31520000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 55111000.0 in Q4 2023 and bottomed at 30135000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 11908000.0 (2023), against an average of 4957176.47.
- The widest annual swing landed in 2024, when Income from Continuing Operations sank 454.02%; it then soared 230.92% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 27486000.0 in 2022, then soared by 100.51% to 55111000.0 in 2023, then tumbled by 143.68% to 24075000.0 in 2024, then jumped by 230.92% to 31520000.0 in 2025, then slumped by 122.85% to 7202000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 7202000.0 (Q1 2026), 31520000.0 (Q4 2025), and 7384000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.20 Mn |
| Dec 31, 2025 | 31.52 Mn |
| Sep 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Mar 31, 2025 | -13.87 Mn |
| Dec 31, 2024 | -24.08 Mn |
| Sep 30, 2024 | -17.70 Mn |
| Jun 30, 2024 | -17.86 Mn |
| Mar 31, 2024 | -12.66 Mn |
| Dec 31, 2023 | 55.11 Mn |
| Sep 30, 2023 | -3.20 Mn |
| Jun 30, 2023 | -11.91 Mn |
| Mar 31, 2023 | -13.26 Mn |
| Dec 31, 2022 | 27.49 Mn |
| Sep 30, 2022 | -11.47 Mn |
| Jun 30, 2022 | -25.97 Mn |
| Mar 31, 2022 | -30.14 Mn |
| Dec 31, 2021 | -27.43 Mn |
| Sep 30, 2021 | -22.43 Mn |
| Jun 30, 2021 | -18.46 Mn |
| Mar 31, 2021 | -19.31 Mn |
| Dec 31, 2020 | -18.75 Mn |
| Sep 30, 2020 | -18.99 Mn |
| Jun 30, 2020 | -18.39 Mn |
| Mar 31, 2020 | -22.58 Mn |
| Dec 31, 2019 | -25.56 Mn |
| Sep 30, 2019 | -17.58 Mn |
| Jun 30, 2019 | -13.29 Mn |
| Mar 31, 2019 | -5.46 Mn |
| Dec 31, 2018 | -10.64 Mn |
| Sep 30, 2018 | -10.46 Mn |
| Jun 30, 2018 | -9.96 Mn |
| Mar 31, 2018 | -10.64 Mn |
| Dec 31, 2017 | -13.86 Mn |
| Sep 30, 2017 | -9.84 Mn |
| Jun 30, 2017 | -10.11 Mn |
| Mar 31, 2017 | -7.61 Mn |
| Dec 31, 2016 | -8.81 Mn |
| Sep 30, 2016 | -7.91 Mn |